Close search box Search


Oxford Cannabinoid Technologies emerged from university research project into potential treatments.

Oxford Cannabinoid Technologies, a biotech company developing medicines that mimic the painkilling effects of cannabis, is to float on the main London market on Friday.

OCT, which started up four years ago with a venture-capital funded programme of research into medical marijuana at Oxford university, will raise £16.5m from the initial public offering, which is heavily oversubscribed. Its valuation after the listing is expected to be about £51.5m. 

Read the full FT story here.

Date posted: 18 May 2021
Article tag: Oxford Cannabinoid Technologies

Related articles

View all news